A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Anemia

In brief

The purpose of the study is to evaluate the efficacy and safety of luspatercept plus best supportive care (BSC) vs placebo plus BSC on anemia in adult participants with α-thalassemia hemoglobin H (HbH) disease and determine the safety and drug levels in adolescent participants.

Key facts

Study ID

NCT05664737

Run by

Bristol-Myers Squibb

People needed

189

Starts

2022-12-09

Expected to finish

2034-08-14

Last updated by the study team

2026-08-10

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult participant≥ 18 years with documented diagnosis of A-Thal HbH disease with Transfusion dependence defined as:.
• i) TD participant: ≥ 6 RBC units during the 24 weeks prior to randomization. ii) NTD participant:< 6 RBC units during the 24 weeks prior to randomization(transfusion due to conditions other than A-Thal will not be considered)and, RBC transfusion-free during at least 8 weeks prior to randomization(unless transfusion was required to treat an acute medical condition other than A-Thal) and, mean baseline Hb ≤ 10 g/dL, based on a minimum of 2 measurements ≥ 1 week apart within 4 weeks prior to randomization; hemoglobin values within 21 days post-transfusion will be excluded.
• Adult participant has Eastern Cooperative Oncology Group (ECOG) 34 score of 0 or 1.
• Adolescent participant 12 years to < 18 years with documented diagnosis of A-Thal HbH disease with transfusion dependence defined as:.
• i) TD participant: ≥ 4 RBC events during the 24 weeks prior to enrollment and, no transfusion-free period for > 56 days during the 24 weeks prior to enrollment. Participants must have a history of regular transfusions for at least 2 years.
• ii) NTD participant:< 4 RBC events during the 24 weeks prior to enrollment and RBC transfusion-free during at least 8 weeks prior to enrollment and, mean baseline Hb ≤ 10 g/dL, based on a minimum of 2 measurements ≥ 1 week apart within 4 weeks prior to enrollment, hemoglobin values within 21 days post-transfusion will be excluded.
• iii) Participant has Karnofsky (age ≥16 years) or Lansky (age < 16 years) performance status score ≥ 50 at screening.

You may not qualify if…

• Medical Conditions: Diagnosis of A-ThalTrait, Hb Bart hydrops, ATRx A-Thal, hemoglobin S/β-thalassemia, myelodysplasia subtype anemia, or with HbE homozygous beta gene mutation. Anemia related to nutritional deficiency, anemia of chronic disease, autoimmune hemolytic anemia, or any other hemolytic anemias. Undergone episodes of hemolysis not related to A-Thal within the 8 weeks prior to randomization. Applicable for the EU only: Bleeding disorders manifested by frequent bleeding episodes (eg, menorrhagia, epistaxis, clotting disorders).
• Participant has deep vein thrombosis (DVT), stroke or other thromboembolic event(s) (except clogged indwelling catheter) requiring medical intervention ≤ 24weeks prior to randomization.
• Participant has uncontrolled hypertension. Controlled hypertension for this protocol is considered: blood pressure value corresponding to ≤Grade 1 according to NCI CTCAE Version 5.0. with or without pharmacological treatment.
• Reproductive Status: Women who are pregnant, plan to get pregnant during the study, or who are breastfeeding.
• Prior/Concomitant: Undergone HSCTs or gene therapy (candidates for HSCT or gene therapy with waiting period of ≥ 12 months are eligible).
• Use of hydroxyurea treatment ≤ 12 weeks prior to enrollment for NTD participants and ≤ 24 weeks for TD participants.
• Participant who has extramedullary hematopoiesis (EMH) complications requiring treatment to control the growth of EMH mass(es) during the screening period.
• Any medical or psychiatric condition (including active infections, recent surgery, sequelae of diseases or interventions, clinically significant laboratory abnormalities or concurrent treatment) that in the opinion of the investigator would put the participant at unacceptable risk of participating in the study or that could affect interpretability of data.
• Other protocol-defined inclusion/exclusion criteria apply.

Where it is running

• The First People's Hospital of Foshan — Foshan, Guangdong, China (enrolling)
• Maoming People's Hospital — Maoming Shi, Guangdong, China (enrolling)
• "Universita degli Studi della Campania ""Luigi Vanvitelli"" - AOU - Clinica Pediatrica" — Naples, Italy (enrolling)
• Hospital Tunku Azizah — Kuala Lumpur, WP, Malaysia (enrolling)
• Hospital Sultanah Aminah — Johor Bahru, Malaysia (enrolling)
• Shenzhen Second People's Hospital — Shenzhen Shi, Guangdong, China (enrolling)
• King Saud University (KSU) - College of Medicine — Riyadh, Saudi Arabia (enrolling)
• KK Women's and Children's Hospital — Singapore, Singapore (enrolling)
• Kaohsiung Medical University Chung-Ho Memorial Hospital — Kaohsiung City, KHH, Taiwan (enrolling)
• National Taiwan University Hospital — Nan Gang Qu, TPE, Taiwan (enrolling)
• China Medical University Hospital — Taichung, TXG, Taiwan (enrolling)
• Siriraj Hospital — Bangkok Noi, Bangkok, Thailand (enrolling)
• Naresuan University Hospital — Mueang Phitsanulok, Thailand (enrolling)
• Hacettepe Üniversitesi Tıp Fakültesi — Altındağ, Turkey (Türkiye) (enrolling)
• Istanbul Universitesi - Istanbul Tip Fakultesi (ITF) Hastanesi — Topkapı, Turkey (Türkiye) (enrolling)
• Liuzhou People's Hospital — Liuzhou, Guangxi, China (enrolling)
• People's Liberation Army The 923rd Hospital — Nanning, GX, China (enrolling)
• Sun Yat-sen Memorial Hospital, Sun Yat-Sen University — Guangzhou, GD, China (enrolling)
• Nanfang Hospital of Southern Medical University — Guangzhou, GD, China (enrolling)
• Hainan General Hospital — Haikou, China (enrolling)
• The First Affiliated Hospital of Guangxi Medical University — Nanning, China (enrolling)
• Local Institution - 0024 — Hong Kong Island, Hong Kong
• Local Institution - 0011 — Haikou, Hainan, China
• Local Institution - 0012 — Kunming, Yunnan, China
• Local Institution - 0005 — Thessaloniki, B, Greece

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.